Central monitoring of depression and anxiety symptoms reduces placebo responses in depression clinical trials: A post hoc exploratory analysis of data from the phase III CCT‐004 trial of vortioxetine-Reference-Cited by-同舟云学术

Central monitoring of depression and anxiety symptoms reduces placebo responses in depression clinical trials: A post hoc exploratory analysis of data from the phase III CCT‐004 trial of vortioxetine

Published:2022-09-24 Issue:4 Volume:42 Page:468-477
ISSN:2574-173X
Container-title:Neuropsychopharmacology Reports
language:en
Short-container-title:Neuropsychopharm Rep

Author:

Watanabe Yoshinori¹,Nishimura Akira²^ORCID,Kikuchi Toshiaki³,Sawada Norifusa⁴,Imazaki Manami⁵,Inada Isao⁵,Watanabe Koichiro⁶

Affiliation:

1. Himorogi Psychiatric Institute Tokyo Japan

2. Pharmaceutical Development Division Towa Pharmaceutical Co., Ltd. Osaka Japan

3. Department of Neuropsychiatry Keio University School of Medicine Tokyo Japan

4. Mental and Sleep Disorder Clinic of Narimasu Tokyo Japan

5. Neuroscience Therapeutic Area Strategy Unit, Takeda Development Center Japan Takeda Pharmaceutical Company Limited Osaka Japan

6. Department of Neuropsychiatry Kyorin University School of Medicine Tokyo Japan

Funder

Takeda Pharmaceutical Co., Ltd.

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Clinical Psychology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/npr2.12288

Reference27 articles.

1. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants

2. Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

3. Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database

4. Is placebo useful in the treatment of major depression in clinical practice?

5. Is high placebo response really a problem in depression trials? A critical re‐analysis of depression studies;Whitlock ME;Innov Clin Neurosci,2019